- Home
- SGMO vs CGTX Comparison
SGMO vs CGTX Comparison
Compare SGMO & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMO
- CGTX
- Stock Information
- Founded
- SGMO 1995
- CGTX 2007
- Country
- SGMO United States
- CGTX United States
- Employees
- SGMO N/A
- CGTX N/A
- Industry
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- SGMO Health Care
- CGTX Health Care
- Exchange
- SGMO Nasdaq
- CGTX Nasdaq
- Market Cap
- SGMO 122.8M
- CGTX 126.2M
- IPO Year
- SGMO 2000
- CGTX 2021
- Fundamental
- Price
- SGMO $0.68
- CGTX $1.55
- Analyst Decision
- SGMO Strong Buy
- CGTX Strong Buy
- Analyst Count
- SGMO 7
- CGTX 3
- Target Price
- SGMO $5.29
- CGTX $2.83
- AVG Volume (30 Days)
- SGMO 5.4M
- CGTX 3.3M
- Earning Date
- SGMO 11-11-2025
- CGTX 11-12-2025
- Dividend Yield
- SGMO N/A
- CGTX N/A
- EPS Growth
- SGMO N/A
- CGTX N/A
- EPS
- SGMO N/A
- CGTX N/A
- Revenue
- SGMO $81,706,000.00
- CGTX N/A
- Revenue This Year
- SGMO $28.47
- CGTX N/A
- Revenue Next Year
- SGMO N/A
- CGTX N/A
- P/E Ratio
- SGMO N/A
- CGTX N/A
- Revenue Growth
- SGMO 565.52
- CGTX N/A
- 52 Week Low
- SGMO $0.41
- CGTX $0.22
- 52 Week High
- SGMO $3.18
- CGTX $3.83
- Technical
- Relative Strength Index (RSI)
- SGMO 66.82
- CGTX 47.42
- Support Level
- SGMO $0.65
- CGTX $1.29
- Resistance Level
- SGMO $0.73
- CGTX $1.55
- Average True Range (ATR)
- SGMO 0.06
- CGTX 0.16
- MACD
- SGMO 0.02
- CGTX -0.02
- Stochastic Oscillator
- SGMO 67.74
- CGTX 51.61
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.